PharmaCyte Biotech, Inc. Quarterly Weighted Average Number of Shares Outstanding, Diluted from Q2 2015 to Q2 2024

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
PharmaCyte Biotech, Inc. quarterly/annual Weighted Average Number of Shares Outstanding, Diluted history and growth rate from Q2 2015 to Q2 2024.
  • PharmaCyte Biotech, Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending July 31, 2024 was 7.87M shares, a 37.6% decline year-over-year.
  • PharmaCyte Biotech, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 9.58M shares, a 50.8% decline from 2022.
  • PharmaCyte Biotech, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 19.5M shares, a 25.6% increase from 2021.
  • PharmaCyte Biotech, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2021 was 15.5M shares, a 972% increase from 2020.
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 7.87M -4.74M -37.6% May 1, 2024 Jul 31, 2024 10-Q 2024-09-17
Q1 2024 9.58M -9.91M -50.8% Feb 1, 2024 Apr 30, 2024 10-K 2024-08-13
Q4 2023 8.61M -10.4M -54.7% Nov 1, 2023 Jan 31, 2024 10-Q 2024-03-18
Q3 2023 8.77M -11.8M -57.4% Aug 1, 2023 Oct 31, 2023 10-Q 2023-12-15
Q2 2023 12.6M -8.23M -39.5% May 1, 2023 Jul 31, 2023 10-Q 2024-09-17
Q1 2023 19.5M +3.97M +25.6% Feb 1, 2023 Apr 30, 2023 10-K 2024-08-13
Q4 2022 19M -2.67M -12.3% Nov 1, 2022 Jan 31, 2023 10-Q 2024-03-18
Q3 2022 20.6M +3.23M +18.6% Aug 1, 2022 Oct 31, 2022 10-Q 2023-12-15
Q2 2022 20.8M +19.2M +1209% May 1, 2022 Jul 31, 2022 10-Q 2023-09-18
Q1 2022 15.5M +14.1M +972% Feb 1, 2022 Apr 30, 2022 10-K 2023-07-31
Q4 2021 21.7M +20.1M +1291% Nov 1, 2021 Jan 31, 2022 10-Q 2023-03-16
Q3 2021 17.4M +15.8M +1028% Aug 1, 2021 Oct 31, 2021 10-Q 2022-12-14
Q2 2021 1.59M +472K May 1, 2021 Jul 31, 2021 10-Q 2022-09-14
Q1 2021 1.45M Feb 1, 2021 Apr 30, 2021 10-K 2022-07-28
Q4 2020 1.56M -1.37B -99.9% Nov 1, 2020 Jan 31, 2021 10-Q 2022-03-15
Q3 2020 1.54M -1.32B -99.9% Aug 1, 2020 Oct 31, 2020 10-Q 2021-12-14
Q2 2020 1.12M* -1.21B May 1, 2020 Jul 31, 2020 10-Q 2021-09-14
Q4 2019 1.38B +249M +22.1% Nov 1, 2019 Jan 31, 2020 10-Q 2021-03-12
Q3 2019 1.33B +244M +22.6% Aug 1, 2019 Oct 31, 2019 10-Q 2020-12-11
Q2 2019 1.21B +164M +15.7% May 1, 2019 Jul 31, 2019 10-Q 2020-09-11
Q1 2019 1.1B +131M +13.6% Feb 1, 2019 Apr 30, 2019 10-K 2020-08-13
Q4 2018 1.13B +151M +15.5% Nov 1, 2018 Jan 31, 2019 10-Q 2020-03-13
Q3 2018 1.08B +108M +11.1% Aug 1, 2018 Oct 31, 2018 10-Q 2019-12-23
Q2 2018 1.05B +121M +13.1% May 1, 2018 Jul 31, 2018 10-Q 2019-09-13
Q1 2018 969M +123M +14.6% Feb 1, 2018 Apr 30, 2018 10-K 2019-08-13
Q4 2017 976M +116M +13.5% Nov 1, 2017 Jan 31, 2018 10-Q 2019-03-14
Q3 2017 973M +124M +14.6% Aug 1, 2017 Oct 31, 2017 10-Q 2018-12-14
Q2 2017 926M +137M +17.4% May 1, 2017 Jul 31, 2017 10-Q 2018-09-12
Q1 2017 845M +92.9M +12.3% Feb 1, 2017 Apr 30, 2017 10-K 2018-07-20
Q4 2016 860M +103M +13.6% Nov 1, 2016 Jan 31, 2017 10-Q 2018-03-19
Q3 2016 849M +104M +13.9% Aug 1, 2016 Oct 31, 2016 10-Q 2017-12-14
Q2 2016 788M +50.3M +6.81% May 1, 2016 Jul 31, 2016 10-Q 2017-09-13
Q1 2016 752M Feb 1, 2016 Apr 30, 2016 10-K 2017-07-27
Q4 2015 757M Nov 1, 2015 Jan 31, 2016 10-Q/A 2017-03-13
Q3 2015 745M Aug 1, 2015 Oct 31, 2015 10-Q 2016-12-02
Q2 2015 738M May 1, 2015 Jul 31, 2015 10-Q 2016-09-06
* An asterisk sign (*) next to the value indicates that the value is likely invalid.